Prevalence and clinical features of LRRK2 mutations in patients with Parkinson's disease in southern Spain

L. Gao, P. Gómez-Garre, F. J. Díaz-Corrales, F. Carrillo, M. Carballo, A. Palomino, J. Díaz-Martín, R. Mejías, P. J. Vime, J. López-Barneo, P. Mir

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


Background and purpose: Mutations in leucine-rich repeat kinase 2 (LRRK2) gene are associated with both familial and idiopathic Parkinson's disease (PD), whereas mutations in PARK2 (PARKIN) gene result in early onset recessive PD. Here, the objectives were to determine the frequency of LRRK2 G2019S and R1441G mutations in a PD population from southern Spain; to search for LRRK2 mutations in familial PD cases and to study the effect of PARKIN mutations on clinical features of LRRK2-associated; PD. Methods: We included 187 PD patients (172 idiopathic, 15 familial) and 287 control subjects from southern Spain. LRRK2 and PARKIN mutations were screened, and clinical features of LRRK2-associated PD were examined. Results: Three (1.7%) idiopathic PD patients carried the G2019S, whereas another three (1.7%) had the R1441G. A novel polymorphism D1420N was found in two (13.3%) familial PD patients. One G2019S carrier also had a homozygous PARKIN deletion, who had early onset PD with clinical symptoms similar to those with PARKIN-associated PD. The remaining LRRK2-asscociated patients had clinical manifestations similar to those with idiopathic PD. Conclusions: G2019S and R1441G are common LRRK2 mutations in PD patients in this region. PARKIN mutations override clinical features in LRRK2-associated PD.

Original languageEnglish (US)
Pages (from-to)957-960
Number of pages4
JournalEuropean Journal of Neurology
Issue number8
StatePublished - Aug 2009
Externally publishedYes


  • Clinical features
  • Genetic study
  • Leucine-rich repeat kinase 2
  • Parkinson's disease

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Prevalence and clinical features of LRRK2 mutations in patients with Parkinson's disease in southern Spain'. Together they form a unique fingerprint.

Cite this